David A. Siegel Beam Therapeutics Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 148,200 shares of BEAM stock, worth $3.47 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

148,200

Holding current value

$3.47 Million

% of portfolio

0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$23.46 - $45.07 $3.48 Million - $6.68 Million	148,200 New	148,200 $4.9 Million
Q2 2023 Aug 14, 2023	SELL	$29.32 - $35.99 $480,848 - $590,236	-16,400 Reduced 65.86%	8,500 $271,000
Q1 2023 May 15, 2023	SELL	$30.15 - $48.79 $648,225 - $1.05 Million	-21,500 Reduced 46.34%	24,900 $762,000
Q4 2022 Feb 14, 2023	SELL	$36.73 - $51.6 $2.01 Million - $2.82 Million	-54,600 Reduced 54.06%	46,400 $1.81 Million
Q3 2022 Nov 14, 2022	BUY	$39.79 - $70.31 $2.01 Million - $3.56 Million	50,600 Added 100.4%	101,000 $4.81 Million

Q2 2022 Aug 15, 2022	BUY	$29.86 - $62.36 $1.5 Million - $3.14 Million	50,400 New	50,400 $1.95 Million
Q1 2022 May 16, 2022	SELL	$53.73 - $82.16 $736,101 - $1.13 Million	-13,700 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$68.02 - $99.06 $3.52 Million - $5.12 Million	-51,700 Reduced 79.05%	13,700 $1.09 Million
Q3 2021 Nov 15, 2021	BUY	$84.37 - $133.6 $1.11 Million - $1.75 Million	13,100 Added 25.05%	65,400 $5.69 Million
Q2 2021 Aug 16, 2021	BUY	$64.12 - $128.71 $3.35 Million - $6.73 Million	52,300 New	52,300 $6.73 Million

Others Institutions Holding BEAM

# of Institutions

241

Shares Held

65.6M

Call Options Held

311K

Put Options Held

777K

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.65B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account